High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence

American Journal of Transplantation

Volumn 10, Issue 7, 2010, Pages 1649-1659

  Chun, J ^a   Kim, W ^b   Kim, B G ^b   Lee, K L ^b   Suh, K S ^c   Yi, N J ^c   Park, K U ^c   Kim, Y J ^a   Yoon, J H ^a   Lee, H S ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Hepatocellular carcinoma; liver transplantation; mutation; recurrence; viral hepatitis

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; GENE MUTATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT CANCER; RECURRENT DISEASE; VIREMIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; INFECTION PREVENTION; INFECTION RISK; LIVER GRAFT REJECTION; LONG TERM CARE; MALE; MONOTHERAPY; POSTTRANSPLANT HEPATITIS B; RISK FACTOR; STEROID THERAPY; VIRUS LOAD; DRUG COMBINATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; MUTATION; PASSIVE IMMUNIZATION; PREDICTIVE VALUE; RETROSPECTIVE STUDY; STATISTICS;

ADULT; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79958037966     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03162.x     Document Type: Article

References (30)

1. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002 8 : 765 774.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991 13 : 619 626.
3. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992 14 : 104 111.
4. Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001 34 : 895 902.
5. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001 34 : 903 910.
6. Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000 6 : 741 748.
7. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005 11 : 402 409.
8. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 329 : 1842 1847.
9. Faria LC, Gigou M, Roque-Afonso AM et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008 134 : 1890 1899 quiz 2155.
10. Yi NJ, Suh KS, Cho JY et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007 13 : 451 458.
11. Pyo Hong S, Keun Kim N, Gyu Hwang S et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004 40 : 837 844.
12. Woo HY, Park H, Kim BI, Jeon WK, Cho YK, Kim YJ. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients. Antivir Ther 2007 12 : 7 13.
13. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003 23 : 5 20.
14. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004 10 : 968 974.
15. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000 6 : 429 433.
16. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005 48 : 133 137.
17. Lo CM, Cheung CK, Lau GK et al. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 2005 5 : 1893 1900.
18. Roche B, Feray C, Gigou M et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003 38 : 86 95.
19. Samuel D, Bismuth H, Bismuth A et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. The Lancet 1991 337 : 813 815.
20. Neff GW, O'Brien C B, Nery J et al. Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004 10 : 1372 1378.
21. Wong PY, McPeake JR, Portmann B, Tan KC, Naoumov NV, Williams R. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma. Am J Gastroenterol 1995 90 : 29 34.
22. Wong SN, Reddy KR, Keeffe EB et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007 13 : 334 342.
23. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002 35 : 1528 1535. (Pubitemid 34966909)
24. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 2005 11 : 716 732.
25. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 33 : 424 432.
26. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 2000 70 : 809 815.
27. Malkan G, Cattral MS, Humar A et al. Lamivudine for hepatitis B in liver transplantation: A single-center experience. Transplantation 2000 69 : 1403 1407.
28. Terrault NA, Zhou S, McCory RW et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998 28 : 555 561.
29. Trautwein C, Schrem H, Tillmann HL et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 1996 24 : 482 488.
30. Bock CT, Tillmann HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002 122 : 264 273.